XOMA Royalty Corp XOMA
News
-
Are AVNS, NUVL, XOMA, TBRG Obtaining Fair Deals for their Shareholders?
-
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—TMHC, CZR, XOMA, and RAMP
-
Are XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders?
-
XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA
-
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation
-
Shareholder Alert: Ademi LLP investigates whether XOMA Royalty Corporation is obtaining a Fair Price for Public Shareholders
-
XOMA Stock Alert: Halper Sadeh LLC is Investigating Whether XOMA Royalty Corporation is Obtaining a Fair Price for its Shareholders
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 17.68M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 1,025.22
- Price/Sales
- 93.91
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 2.17%
Company Profile
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 14
- Website
- https://www.xoma.com
Valuation
|
Metric
|
XOMA
|
|---|---|
Price/Earnings (Normalized) | 1,025.22 |
Price/Book Value | 4.24 |
Price/Sales | 93.91 |
Price/Cash Flow | 49.70 |
Price/Earnings
XOMA
Financial Strength
|
Metric
|
XOMA
|
|---|---|
Quick Ratio | 3.31 |
Current Ratio | 3.59 |
Interest Coverage | 3.62 |
Quick Ratio
XOMA
Profitability
|
Metric
|
XOMA
|
|---|---|
Return on Assets (Normalized) | 8.30% |
Return on Equity (Normalized) | 21.44% |
Return on Invested Capital (Normalized) | 14.04% |
Return on Assets
XOMA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@CSQ%> | LOCK|!p>$w | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&#!?@?T | LOCK|$^m$$ | $71B | |||
| argenx SE ADR
ARGX
| LOCK|%^@BZ> | LOCK|?x& | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!dnd&k | LOCK|>ny | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!!m#>$H | LOCK|%y>ZM | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|SQly@$Fh | LOCK|@J<! | $26B | |||
| Moderna Inc
MRNA
| LOCK|g$%^#@j | LOCK|T^ | $25B | |||
| Incyte Corp
INCY
| LOCK|^Yg!CB | LOCK|L<Q | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|k&>d%k | LOCK|m^% | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|#yG<^F | LOCK|@?h | $16B |
United States